An excellent point, and one that I'd missed!Hallucigenia wrote:It's always a balance - introducing more epitopes means more risk of side-effects from cross-reactions. A wider response is not always A Good Thing. So if you've got epitopes that seem to produce a remarkably good response, then the balance of risk would be against adding more epitopes.stevensfo wrote:Whenever possible, the drug companies should switch to using real viral particles as vaccine. As with real infections, this will produce a wider antibody response.
Steve